Background: To assess the response of patients with soft tissue sarcoma (STS) to the combination of docetaxel, bevacizumab, and gemcitabine. Vascular endothelial growth factor (VEGF)-A levels and expression of VEGF-A and VEGF receptors 1 and 2 were evaluated.
introduction
The two most active single agents for salvage chemotherapy of patients with soft tissue sarcoma (STS) refractory to anthracyclines are docetaxel with 0%-17% overall response rate based on three studies with 109 patients [1] [2] [3] , and gemcitabine with a published response rate varying from 3% to 11% based on a pool of 131 patients [4] [5] [6] [7] [8] [9] . The combination of these two drugs yielded a 53% overall remission rate with 20% stable disease (SD) and an overall survival (OS) of 17.9 months in one study [10] and an 18.4% overall remission rate (24.2% for the leiomyosarcoma subtype) and an overall survival of 12.1 months in the other study [11] . In this combination, gemcitabine is administered i.v. on days 1 and 8 at 900 mg/m 2 over 90 min and docetaxel on day 8 at 100 mg/m 2 . Treatment is repeated every 21 days until progression of disease (PD). The combination may be superior to gemcitabine alone [12] . Grade 3 and 4 adverse events are common and granulocyte colony stimulating factor necessary to alleviate side-effects of neutropenia. Vascular endothelial growth factor (VEGF) is a potent tumor-produced angiogenic factor that could been associated with clinical outcomes of patients with sarcoma [13] [14] [15] [16] [17] . Two phase II studies of bevacizumab, a monoclonal antibody against VEGF, in combination with either doxorubicin or temozolomide have been published. Seventeen patients were treated with doxorubicin at 75 mg/m 2 followed by bevacizumab 15 mg/kg every 3 weeks. The response rate was 12% and 65% had stable disease. Eight patients developed cardiac toxicity grade 2-4 at low cumulative doses of doxorubicin (range = 75-600 mg/m 2 ). One patient with extensive lung disease died of bilateral pneumothoraces. The regimen was too cardiotoxic to be of practical use [18] . Temozolomide of 150 mg/m 2 was administered orally on days 1-7 and days [15] [16] [17] [18] [19] [20] [21] with bevacizumab 5 mg/kg i.v. on days 8 and 22, every 28 days to patients with hemangiopericytoma or solitary fibrous tumor. Fourteen patients with measurable disease including 8 with metastatic disease were enrolled. The best response assessment using Choi criteria was a 79% partial response (PR) rate and a median progression-free interval of 6.3 months [19] . In this study, we added bevacizumab to the combination of gemcitabine and docetaxel. In order to render the chemotherapy less toxic while preserving the dose intensity of the regimen, we used an every 2-week schedule. The aims of the study were to determine the maximum tolerated dose for gemcitabine in combination with a fixed dose of docetaxel and bevacizumab and to obtain preliminary data on the efficacy and toxicity profile of the combination in an expansion cohort. Lastly, a translational exploratory end point looked at the levels of VEGF in plasma and at the baseline protein expression of VEGF-A, VEGF-R1, and VEGF-R2 by immunohistochemistry (IHC).
patients and methods
The study was approved by the UNM Institutional Review Board (ClinicalTrials.gov Identifier: NCT00276055). Gemcitabine was provided free of charge to enrolled patients by Eli Lilly and Company, who also sponsored part of the translational studies. Standard commercial supply of docetaxel and bevacizumab was used.
patients
Patients were eligible to participate if they had never received chemotherapy, were >16 years, had measurable disease, a life expectancy >12 weeks, a Zubrod performance status of 0-2, and had signed an informed consent. The granulocyte count must have been >1500 cells/mm 3 , the hemoglobin level >8.0 g/dl, the platelet count >100 000/mm 3 , the bilirubin <2 mg/dl, the transaminases lower than twice the upper limit of normal, and the creatinine lower than 1.5 times the upper limit of normal. Patients with symptomatic brain metastases, concurrent chemotherapy or radiation therapy, or severe medical problems were excluded.
treatment
The treatment was given every 2 weeks on day 1. Docetaxel was at a fixed dose of 50 mg/m 2 and bevacizumab at a fixed dose of 5 mg/kg administered after the chemotherapy. The gemcitabine dose was increased in the phase I part of the study following a standard 3 + 3 design. . A total of 12 doses were planned. Patients who were candidates for a curative surgery could receive the same regimen in a neoadjuvant fashion, if their primary tumor was of high grade and >5 cm (except for angiosarcoma). In case of neoadjuvant chemotherapy, eight doses were planned, with the first four doses given with bevacizumab and the four last doses given without it, in order to prevent wound healing problems in the postoperative period.
evaluation during treatment
A physical examination was done every 4 weeks. Cell count, liver and kidney functions were tested before each treatment administration. Computerized scans were repeated every 8 weeks. RECIST 1.0 criteria were used. All films were reviewed by two expert radiologists (SE and BS) blinded to any clinical information, for confirmation of clinical response.
quantification of VEGF levels in serum A blood sample for VEGF was drawn before the first treatment, after four doses, and when the patient came off study (see supplemental data for technique, available at Annals of Oncology online). Control blood was obtained from 12 anonymized healthy volunteers without a history of cancer [20] .
VEGF IHC of tumor sections
Expression of VEGF-A, VEGF-R1, and VEGF-R2 was assessed in paraffin-embedded biopsies from the primary tumor by IHC. Sections of 5 lm were stained with VEGF-A (Biocare, Concord, CA), VEGF-R1, and VEGF-R2 (Abcam, Cambridge, MA) (see supplemental data for technique, available at Annals of Oncology online). Two pathologists (TB and LC) blinded to clinical information interpreted the stained slides. Cases with discordant scores were reevaluated to obtain a consensus score.
statistics Dose-limiting toxic effects (DLTs) were based upon the NCI CTCAE version 3 and defined as the dose of drug that produces a grade 4 hematological toxicity lasting >7 days, or grade 3 or more (grade 2 for neurotoxicity) nonmyelosuppressive toxicity in >33% of patients treated at a given dose level during the first two doses of treatment. The maximum tolerated dose was defined as the highest dose for which no more than one of six patients developed a DLT. For the phase II part of the study, a Simon's two-stage optimum design was used, with a null hypothesis that the overall response rate was £15% versus an alternative hypothesis that the overall response rate was ‡40%. At the first stage, seven assessable patients were enrolled. If one or no responses occurred, the trial would have been terminated; otherwise another 18 fully assessable patients were treated for a total of 25 patients. If the total number of responses were ‡7 among the 25 assessable patients, this combination would be considered worthy of further testing. This optimum design had a probability of 0.806 for concluding that the drug is effective when the real response rate is ‡40% for the targeted power of 80%. The actual probability of concluding that this treatment was not effective when it was actually effective was 4.9% for the targeted type I error = 5%. The probability of early termination of trial was 0.717.
Survival analysis for overall survival and progression-free survival (PFS) was conducted using Kaplan-Meier product estimate with its 95% confidence interval (CI). The statistical significance of VEGF-A serum level changes from baseline to after two courses of chemotherapy was tested using a two-sample t-test. Pearson's correlation test and simple linear regression were used to examine correlations among VEGF-A serum levels and tissue expressions of VEGF-A, VEGF-R1, and VEGF-R2. Cox proportional hazard regression was used to test any significant effect of biomarkers on OS and PFS.
results Thirty-eight patients were enrolled in the study. Two were not assessable for toxicity and response (one did not receive bevacizumab and one did not complete two doses). Another patient treated in the neoadjuvant setting was assessable for toxicity only (she did not complete four full doses). Table 1 shows patient characteristics. Fifteen patients were treated in the neoadjuvant setting and 20 for metastatic disease. Table 2 shows the adverse events observed after the first two doses in nine patients treated in the phase I part. No DLTs were observed at 1000, 1250, and 1500 mg/m 2 dose levels of gemcitabine, but two responses were seen [one clinical complete response (CR) in a man with an angiosarcoma and one PR in a man with undifferentiated sarcoma], 5 SD (three leiomyosarcoma, one liposarcoma, one peripheral nerve sheath tumor [PNST]), and two PD (PNST and undifferentiated sarcoma). These clinical responses and the good tolerance rate led to the completion of the phase II part of the study. The predetermined maximum dose of gemcitabine (1500 mg/m 2 ) was thus combined to docetaxel 50 mg/m 2 and bevacizumab 5 mg/kg. An additional 27 patients (one assessable for toxicity only) were treated at this dose to better define the toxicity profile and the efficacy of this regimen. Table 3 shows the side-effects observed during this study. The most remarkable observation is the lack of significant hematologic toxicity with an active regimen for the treatment of sarcoma. The most common complaint was fatigue. Gastrointestinal symptoms, mucositis, alopecia, and myalgia were mild but common. Epiphora was initially an issue and necessitated stenting of the lachrymal duct in two cases (5%). The protocol was modified to use prophylactic eye drops of dexamethasone 0.1% twice a day starting the day before, the day of, and the day after each treatment; after which, no patient required lachrymal duct stenting.
The most serious side-effects were related to bevacizumab. A bowel perforation was seen in a 78-year-old male with a leiomyosarcoma originating in the cecum, an expected event given the anatomical presentation. The patient died of a pulmonary embolism in the postoperative setting. A pneumothorax related to the rapid shrinkage of the lung metastases was seen in a patient with myxoid liposarcoma. He was treated with pleural suction and recovered fully and resumed treatment without further problems and had a PR that lasted for 10 months. The patient assessable for toxicity only had an angiosarcoma of the breast. She suffered an ulceration of the skin from tumor necrosis and was operated without completing the treatment per protocol. While the percentage of all adverse events attributed to bevacizumab was only 17% (30/ 179), the relative proportion of grade 2 or greater side-effects (including grade 4) from bevacizumab was 36% (11/30), and from chemotherapy (all grade 2, except for two events of grade 3 fatigue) was only 20% (30/149) ( Table 3) .
The overall response rate for all 35 patients is 31.4% (95% CI 17% to 49%), with a clinical benefit rate of 82.8% ( Figure S2 , available at Annals of Oncology online). Of the 15 assessable patients treated in the neoadjuvant setting, two with undifferentiated sarcomas progressed and were switched to a standard doxorubicin and ifosfamide regimen, but did not respond to this treatment either. One had surgery and the other one was not a surgical candidate because of rapid progression of disease. There were five CRs, two pathological and three clinical, one PR, and seven SD. Of these, two never had surgery (angiosarcoma and undifferentiated sarcoma). Interestingly, the two pathological CRs were not in clinical CRs at the time of surgery (angiosarcoma and undifferentiated sarcoma). The median tumor bulk before chemotherapy in these 15 patients was 10 cm (range = 0.5-40 cm). Three of these 15 patients died of recurrence, one with primary resistant disease (undifferentiated sarcoma of the back), one with SD (leiomyosarcoma of the thigh), and one with a facial angiosarcoma who had a clinical CR after chemotherapy and had also received adjuvant radiotherapy. Two additional patients recurred; one with undifferentiated sarcoma who was in clinical complete remission recurred 6 months later with lung metastases; and one with primary resistance, who was operated and radiated, recurred 3 years later, respectively; both are still alive with disease. Therefore, after multidisciplinary care using this new neoadjuvant chemotherapy combination followed by surgery and adjuvant radiotherapy as indicated, 67% of patients remain free of disease at a median follow-up of 36 months. All side-effects were completely reversible in these patients.
Of the 20 patients treated for metastatic disease, four patients progressed after two courses of treatment. Two responded to a doxorubicin-based salvage regimen and the other two did not. Eleven patients had SD and received a median of six courses (range = 2-10 courses). Five patients had a PR and received a median of six courses (range= 3-8 courses). The median OS for this group of patients is 11 months (95% CI 8.1-22.2 months). The PFS is 5 months (95% CI 4-11 months) (supplemental Figure S1 , available at Annals of Oncology online). The mean VEGF-A level in normal controls was 36.7 pg/ml (range = 12.4-99.2) [21] . VEGF-A levels before treatment were 160.6 6 31.6 pg/ml (range = 9.6-717.5; P < 0.01; supplemental Figure S2 , available at Annals of Oncology online). As expected with bevacizumab, VEGF-A levels drastically decreased after treatment, close to normal levels (mean 37.6 6 8.3; P < 0.01), but reincreased after the end of treatment (128.6 6 29.9; P = 0.64 compared with baseline and P = 0.03 compared with normal controls) (data not shown because of various reasons and timings for end of treatment). There were no statistically significant correlations among VEGF-A plasma levels and tissue expressions of VEGF-A, VEGF-R1, and VEGF-R2. Based on the Cox proportional hazard regression, VEGF-A and VEGF-R1, and VEGF-R2 expressions did not have a significant effect on OS or PFS (data not shown). PRs were also observed in myxoid liposarcoma, synovial sarcoma, and adenosarcoma of the uterus. Despite the small number of patients, the observed response rate and the median survival compare favorably to published results of 30% remission rate with the combination of docetaxel and gemcitabine and with the frontline results seen with the standard combination of doxorubicin and ifosfamide [22] [23] [24] [25] .
Most noteworthy is the lack of toxicity seen with the combination, except for the rare known but life-threatening side-effects of bevacizumab. Table 3 describes the differential toxicity between chemotherapy and the addition of bevacizumab. When compared with the 3-week regimen of gemcitabine and docetaxel (Table 5) , the 2-week regimen is devoid of significant hematologic side-effects (compare Tables 3  and 5 ). The nonhematologic side-effects were also milder than in the 3-week schedule. The main adverse events related to docetaxel were nail atrophy and epiphora-to the combination were fatigue, gastrointestinal side-effects, dyspnea, myalgia, and alopecia-and to bevacizumab were bowel perforation, wound dehiscence, and possibly pneumothorax. To avoid epiphora, the protocol was modified to require steroid eye drops concurrently to the standard oral steroid premedication for docetaxel.
While taxanes are known to induce response in angiosarcomas [26] [27] [28] [29] [30] , the complete pathological responses observed in this histology may be partly due to the use of bevacizumab [31] . Similarly, of 122 assessable patients with various histological subtypes treated with sorafenib, the only subtype that met the primary RECIST end point was angiosarcoma with a response rate of 14%. However, there was no correlation between phosphorylated extracellular signalregulated kinase expression and response in six patients with angiosarcoma with paired pre-and posttherapy biopsies [32] .
The hypothesis that angiosarcoma growth is stimulated by VEGF, and therefore that bevacizumab may be important for the care of angiosarcoma needs further study. Contrary to the reported sensitivity of leiomyosarcoma to gemcitabine and docetaxel, this 2-week administration only yielded stability of disease in this histology. We do not have an explanation for this observation.
The correlative studies about bevacizumab included VEGF receptors 1 and 2 and its ligand. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) [33] . VEGFR-2 appears to mediate almost all the known cellular responses to VEGF. VEGFR-1 may modulate VEGFR-2 signaling, perhaps as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (particularly important during vasculogenesis in the embryo). Serum levels of VEGF-A decreased after bevacizumab (supplemental Figure S2 , available at Annals of Oncology online), but neither this decrease nor the expression of VEGF receptors in tissue correlated to patient outcome.
Overexpression of VEGF is correlated to shorter survival (23 versus 52 months; P = 0.01), especially in patients with leiomyosarcoma (7.5 versus 76 months, P = 0.03) [15] . Median pretreatment serum VEGF levels are higher in sarcoma versus benign tumors (450 versus 233 pg/ml), and persistent overexpression is linked to residual disease [34] . Kinase inhibitors of VEGFR have been studied in patients with sarcoma with mixed results. Sunitinib malate [35] [36] [37] , sorafenib [32] , pazopanib [38] , and semaxanib [39] all had minimal activity but induced stable disease at 12 weeks in 40%-80% of patients. The same outcome was seen with ABT-510, which inhibits angiogenesis via a novel thrombospondin-mimetic mechanism, with a 40% progression-free interval at 12 weeks [40] . The role of angiogenesis inhibition for the treatment of sarcoma is currently unclear.
The observations made in this study may be worthwhile for the care of patients with sarcomas because this regimen is less toxic than any other standard chemotherapy in use for this patient population. Additionally, this is an active regimen, probably not cross-resistant with the anthracycline-based regimens, offering an additional choice for the patients with sarcomas. However, the benefit of antiangiogenic treatment could not be defined in this study and will require additional clinical trials.
In conclusion, the combination of gemcitabine, docetaxel, and bevacizumab may be an active regimen for STS and is well tolerated when given on an every 2-week schedule. However, the role of bevacizumab needs to be ascertained in a randomized trial. This regimen should be tested further in patients with angiosarcoma or undifferentiated sarcomas.
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